Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report

Conclusions We demonstrate that, even in patients with atypical hemolytic uremic syndrome and prolonged dialysis dependence, recovery of renal function can be seen with eculizumab treatment. We suggest a treatment regime of at least three months prior to evaluation of efficacy.
Source: Journal of Medical Case Reports - Category: Journals (General) Source Type: research